Development and evaluation of tofacitinib transdermal system for the treatment of rheumatoid arthritis in rats

References

• Lundquist LM, Cole SW, Sikes ML. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. WJO. 2014;5(4):504–511.
   Google Scholar
• Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183–196.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2018;17(1):78–78.
   Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66(1):311–328.
   PubMedGoogle Scholar
• Menet CJ, Rompaey LV, Geney R. Advances in the discovery of selective JAK inhibitors. In: Lawton G, Witty DR, editors. Progress in medicinal chemistry. Amsterdam (The Netherlands): Elsevier; 2013. Vol. 52, p. 153–223.
   Google Scholar
• Padjen I. Drugs used in rheumatic disease. In: Atzeni F, Masala IF, Aletaha D, Lee M, Baraliakos X, editors. Handbook of systemic autoimmune diseases. Amsterdam (The Netherlands): Elsevier; 2018. Vol. 15, p. 39–76.
   Google Scholar
• Cohen S. Novel intra-cellular targeting agents in rheumatic disease. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR, editors. Kelley and Firestein’s textbook of rheumatology. 10th Ed. Amsterdam (The Netherlands): Elsevier; 2017. p. 1044–1060.
   Google Scholar
• [email protected]. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib: FDA Drug Safety Communication. Washington (DC): U.S. Food and Drug Administration. [cited 2019 Dec 21]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and
   Google Scholar
• pubchem.ncbi.nlm.nih.gov. . Tofacitinib: Compound Summary. Maryland (MD): National Library of Medicine; PubChem Compounds. [cited 2019 Aug 21]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tofacitinib
   Google Scholar
• go.drugbank.com. Tofacitinib citrate. Product ingredient for Tofacitinib. [cited 2019 Aug 20]. Available from: https://www.drugbank.ca/salts/DBSALT000180
   Google Scholar
• Lee JS, Kim SH. Dose-dependent pharmacokinetics of tofacitinib in rats: influence of hepatic and intestinal first-pass metabolism. Pharmaceutics. 2019;11(7):318.
   PubMed Web of Science ®Google Scholar
• Attia SM. Deleterious effects of reactive metabolites. Oxid Med Cell Longevity. 2010;3(4):238–253.
   PubMed Web of Science ®Google Scholar
• Halder J, Gupta S, Kumari R, et al. Microneedle array: applications, recent advances, and clinical pertinence in transdermal drug delivery. J Pharma Innov. 2020;2020:1–8.
   Google Scholar
• Yang J, Liu X, Fu Y, et al. Recent advances of microneedles for biomedical applications: drug delivery and beyond. Acta Pharmaceutica Sinica B. 2019;9(3):469–483.
   PubMed Web of Science ®Google Scholar
• Bhatia C, Monika S, Bajpai M. Formulation and evaluation of transdermal patch of pregabalin. Int J Pharm Sci Res. 2012;3:569–575.
   Google Scholar
• Mogusala V, Venisetty RK. Fabrication of microneedle molds and polymer based biodegradable microneedle patches: a novel method. Am J Drug Deliv Therap. 2015;2:1–12.
   Google Scholar
• Park JH, Allen MG, Prausnitz MR. Polymer microneedles for controlled-release drug delivery. Pharm Res. 2006;23(5):1008–1019.
   PubMed Web of Science ®Google Scholar
• Chen MC, Ling MH, Kusuma SJ. Poly-γ-glutamic acid microneedles with a supporting structure design as a potential tool for transdermal delivery of insulin. Acta Biomater. 2015;24:106–116.
   PubMed Web of Science ®Google Scholar
• Maurya A, Rangappa S, Bae J, et al. Evaluation of soluble fentanyl microneedles for loco-regional anti-nociceptive activity. Int J Pharm. 2019;564:485–491.
   PubMedGoogle Scholar
• Sharma A, Upadhyay DK, Sarma GS, et al. Squalene integrated NLC based gel of tamoxifen citrate for efficient treatment of psoriasis: a preclinical investigation. J Drug Delivery Sci Technol. 2020;56:101568.
   Web of Science ®Google Scholar
• Larrañeta E, Moore J, Vicente-Pérez EM, et al. A proposed model membrane and test method for microneedle insertion studies. Int J Pharm. 2014;472(1–2):65–73.
   PubMedGoogle Scholar
• Li X-y, Li H, Zhang Y, et al. Development of albumin coupled, cholesterol stabilized, lipid nanoemulsion of methotrexate, and TNF-α inhibitor for improved in vivo efficacy against rheumatoid arthritis. AAPS PharmSciTech. 2017;18(7):2774–2782.
   PubMed Web of Science ®Google Scholar
• Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharma. 2016;7(2):27–31.
   PubMedGoogle Scholar
• Rai VK, Sinha P, Yadav KS, et al. Anti-psoriatic effect of Lavandula angustifolia essential oil and its major components linalool and linalyl acetate. J Ethnopharmacol. 2020;261:113127.
   PubMed Web of Science ®Google Scholar
• Sinha P, Srivastava N, Rai VK, et al. A novel approach for dermal controlled release of salicylic acid for improved anti-inflammatory action: combination of hydrophilic-lipophilic balance and response surface methodology. J Drug Delivery Sci Technol. 2019;52:870–884.
   Web of Science ®Google Scholar
• Kim JE, Park MY, Kim SH. Simple determination and quantification of tofacitinib, a JAK inhibitor, in rat plasma, urine and tissue homogenates by HPLC and its application to a pharmacokinetic study. J Pharm Investig. 2020;50(6):603–612.
   Web of Science ®Google Scholar
• Paudel KS, Milewski M, Swadley CL, et al. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv. 2010;1(1):109–131.
   PubMedGoogle Scholar
• John L, Kumar A, Samuel S. Formulation and evaluation of amlodipine transdermal patches using ethyl cellulose. Int Res J Pharm. 2013;4(10):84–88.
   Google Scholar
• Singh A, Bali A. Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride. J Anal Sci Technol. 2016;7(1):25.
   Web of Science ®Google Scholar
• Liu S, Jin M-n, Quan Y-s, et al. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin. J Controlled Release. 2012;161(3):933–941.
   PubMed Web of Science ®Google Scholar
• Kumar A. Development and evaluation of sustained release matrix transdermal patches of Nano carvedilol. Int J Res Pharma Sci. 2013;4:321–327.
   Google Scholar
• Hartwig A. Polyethylene glycols (PEGs) (average molar mass 200–600). The MAK Collect Occup Health Safe. 2020;5:1–16.
   Google Scholar
• Waghule T, Singhvi G, Dubey SK, et al. Microneedles: a smart approach and increasing potential for transdermal drug delivery system. Biomed Pharmacother. 2019;109:1249–1258.
   PubMed Web of Science ®Google Scholar